The chief executive of ASX-listed medtech Anteris Technology says its replacement heart valve will take “at least” 50 per cent of the $10 billion sector when it comes to market, which could one day value the company at $25 billion.
Anteris has developed a unique heart valve called the DurAVR, which has emerged as a contender in the race to create a human-like valve replacement for patients who suffer from aortic stenosis.
Loading...
Tess Bennett is a technology reporter with The Australian Financial Review, based in the Brisbane newsroom. She was previously the work & careers reporter. Connect with Tess on Twitter. Email Tess at tess.bennett@afr.com
